INmune Bio Stock (NASDAQ:INMB)
Previous Close
$4.57
52W Range
$4.45 - $14.74
50D Avg
$5.30
200D Avg
$7.86
Market Cap
$100.66M
Avg Vol (3M)
$234.09K
Beta
1.85
Div Yield
-
INMB Company Profile
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
INMB Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CUE | Cue Biopharma, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| DRMA | Dermata Therapeutics, Inc. |
| AVXL | Anavex Life Sciences Corp. |
| ANTX | AN2 Therapeutics, Inc. |
| BIVI | BioVie Inc. |
| TCRX | TScan Therapeutics, Inc. |
| TFFP | TFF Pharmaceuticals, Inc. |
| INAB | IN8bio, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| PYPD | PolyPid Ltd. |
| SAVA | Cassava Sciences, Inc. |
| CGTX | Cognition Therapeutics, Inc. |
| ANIX | Anixa Biosciences, Inc. |